Bausch Health Cos EBITDA 2010-2024 | BHC

Bausch Health Cos ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Bausch Health Cos Annual EBITDA
(Millions of US $)
2023 $2,292
2022 $1,947
2021 $2,057
2020 $2,562
2019 $1,935
2018 $514
2017 $3,111
2016 $2,418
2015 $4,139
2014 $3,685
2013 $1,696
2012 $1,102
2011 $940
2010 $166
2009 $319
Bausch Health Cos Quarterly EBITDA
(Millions of US $)
2024-09-30 $613
2024-06-30 $761
2024-03-31 $615
2023-12-31 $705
2023-09-30 $343
2023-06-30 $739
2023-03-31 $505
2022-12-31 $129
2022-09-30 $601
2022-06-30 $558
2022-03-31 $659
2021-12-31 $743
2021-09-30 $973
2021-06-30 $146
2021-03-31 $195
2020-12-31 $439
2020-09-30 $909
2020-06-30 $470
2020-03-31 $744
2019-12-31 $-570
2019-09-30 $866
2019-06-30 $803
2019-03-31 $836
2018-12-31 $588
2018-09-30 $838
2018-06-30 $560
2018-03-31 $-1,472
2017-12-31 $548
2017-09-30 $770
2017-06-30 $865
2017-03-31 $928
2016-12-31 $886
2016-09-30 $-123
2016-06-30 $837
2016-03-31 $818
2015-12-31 $887
2015-09-30 $1,195
2015-06-30 $1,069
2015-03-31 $989
2014-12-31 $983
2014-09-30 $1,158
2014-06-30 $774
2014-03-31 $770
2013-12-31 $653
2013-09-30 $82
2013-06-30 $493
2013-03-31 $468
2012-12-31 $237
2012-09-30 $274
2012-06-30 $308
2012-03-31 $283
2011-12-31 $211
2011-09-30 $280
2011-06-30 $248
2011-03-31 $201
2010-12-31 $101
2010-09-30 $-79
2010-06-30 $88
2010-03-31 $56
2009-12-31 $104
2009-09-30 $101
2009-06-30 $39
2009-03-31 $75
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $3.012B $8.757B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00